Dr Sophie Whyte MMath (Warwick), PhD (Birmingham)
HEDS, ScHARR
The University of Sheffield
Regent Court
30 Regent Street
Sheffield
S1 4DA
UK
Office:
Tel: (+44) (0)114 222 0859
Fax: (+44) (0)114 272 4095
E-mail: sophie.whyte@sheffield.ac.uk
Biography
I joined the HEDS section of ScHARR as a mathematical modeller in September 2007. Previous to this, I obtained a Masters in Mathematics from the University of Warwick and a PhD in Pure Mathematics (Group Theory) from Birmingham University.
Research interests
I currently work for the Policy Research Unit in Economic Evaluation of Health and Care Intervention (EEPRU) www.eepru.co.uk/
I am particularly interested in the calibration of disease natural history models. In particular I have used the Metropolis Hastings algorithm to calibrate a natural history model for colorectal cancer within a Bayesian framework.
I have undertaken several research projects in the area of colorectal cancer including:
- economic evaluation of early awareness campaigns for colorectal cancer,
- a reappraisal of the options for colorectal cancer screening in England,
- an analysis of the guaiac FOBT referral algorithm within the current Bowel Cancer Screening Programme,
- modelling the resource implication of the age extension of the current bowel cancer screening programme,
- economic evaluation of the options for colorectal cancer screening in Ireland,
- an economic evaluation of a new diagnostic test for colorectal cancer.
My work also involves technology appraisal for the National Institute for Health and Clinical Excellence (NICE).
Teaching interests
I undertake teaching on the MSc in Health Economics and Decision Modelling and on the MSc in Public Health.
Key publications
- Whyte,S; Chilcott,J; Essat,M; Stevens,J; Wong,R; Kalita,N, Reappraisal of the options for colorectal cancer screening, Report for the NHS Bowel Cancer Screening Programme, www.screening.nhs.uk/policydb_download.php
- Whyte S, Walsh C, Chilcott J. Bayesian calibration of a natural history model with application to a population model for colorectal cancer. Medical Decision Making 2010, Medical Decision Making, 2011 Jul-Aug;31(4):625-41. Epub 2010 Dec 2. mdm.sagepub.com/content/31/4/625.long Example Excel model using the Metropolis Hastings algorithm to calibrate a state transition model available to down load download example file.
- Whyte S, Pandor A, Stevenson M, Rees A. Bevacizumab within its licensed indication in combination with oxaliplatin and either 5FU or capecitabine for the treatment of metastatic colorectal cancer. Health Technology Assessment 2010;14 suppl 2. www.hta.ac.uk/erg/supplements/supplement1402.pdf#nameddest=article07
- Whyte S, Cooper KL, Stevenson MD, Madan J, Akehurst R. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer: modelling different prophylaxis strategies. Value in Health 2011;14(4):465-474.
- Sharp L, Céilleachair A, Comber H et al. Options for a population-based colorectal cancer screening programme in Ireland: a health technology assessment. 2009. A report for the Health Information & Quality Authority. www.hiqa.ie/healthcare/health-technology-assessment/colorectal-cancer-screening
